MXPA04005068A - Regimen de dosis de eritropoyetina para el tratamiento de la anemia. - Google Patents

Regimen de dosis de eritropoyetina para el tratamiento de la anemia.

Info

Publication number
MXPA04005068A
MXPA04005068A MXPA04005068A MXPA04005068A MXPA04005068A MX PA04005068 A MXPA04005068 A MX PA04005068A MX PA04005068 A MXPA04005068 A MX PA04005068A MX PA04005068 A MXPA04005068 A MX PA04005068A MX PA04005068 A MXPA04005068 A MX PA04005068A
Authority
MX
Mexico
Prior art keywords
erythropoietin
dosing regimen
treating anemia
present
new
Prior art date
Application number
MXPA04005068A
Other languages
English (en)
Inventor
Francis Farrell
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of MXPA04005068A publication Critical patent/MXPA04005068A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona un nuevo regimen de dosis de inyeccion subcutanea para eritropoyetina para el tratamiento de la anemia; el nuevo regimen de tratamiento con eritropoyetina de la presente invencion da como resultado niveles aumentados de hemoglobina con una administracion de dosis menos frecuente.
MXPA04005068A 2001-11-28 2002-11-26 Regimen de dosis de eritropoyetina para el tratamiento de la anemia. MXPA04005068A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33395801P 2001-11-28 2001-11-28
PCT/US2002/037982 WO2003045423A1 (en) 2001-11-28 2002-11-26 Erythropoietin dosing regimen for treating anemia

Publications (1)

Publication Number Publication Date
MXPA04005068A true MXPA04005068A (es) 2004-08-19

Family

ID=23304949

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005068A MXPA04005068A (es) 2001-11-28 2002-11-26 Regimen de dosis de eritropoyetina para el tratamiento de la anemia.

Country Status (9)

Country Link
US (1) US7232797B2 (es)
EP (1) EP1461065A1 (es)
JP (1) JP2005530678A (es)
AU (1) AU2002357019A1 (es)
BR (1) BR0214557A (es)
CA (1) CA2468499A1 (es)
MX (1) MXPA04005068A (es)
NZ (1) NZ532988A (es)
WO (1) WO2003045423A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20050282751A1 (en) * 2004-03-19 2005-12-22 Ajinomoto Co., Inc. Therapeutic agent for renal anemia
US7879361B2 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
US8216994B2 (en) * 2009-11-09 2012-07-10 Ecolab Usa Inc. Phosphate functionalized alkyl polyglucosides used for enhanced food soil removal
JP6223821B2 (ja) * 2010-03-23 2017-11-01 フレゼニウス メディカル ケア ドイチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 赤血球生成刺激剤（ｅｓａ）の効果を予測し投与量を決定するための方法及び装置
US9057731B2 (en) 2010-06-23 2015-06-16 University Of Louisville Research Foundation, Inc. Methods and kits for predicting a response to an erythropoietic agent
HUE035444T2 (en) * 2010-08-03 2018-05-28 Fresenius Medical Care Deutschland Gmbh Methods and Equipment for Predicting the Effects of Erythropoiesis Stimulating Agents (ESAs) and Determining an Injectable Dose
US10319478B2 (en) * 2011-09-08 2019-06-11 Fresenius Medical Care Holdings, Inc. System and method of modeling erythropoiesis and its management
WO2013049624A1 (en) 2011-09-30 2013-04-04 University Of Louisville Research Foundation, Inc. System and method for personalized dosing of pharmacologic agents
US10049187B2 (en) 2012-09-14 2018-08-14 University Of Massachusetts Methods and devices for determining optimal agent dosages
WO2018011302A1 (en) * 2016-07-12 2018-01-18 Hexal Ag Glycoprotein with reduced acetylation rate of sialic acid residues

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
PT964702E (pt) 1996-08-02 2006-12-29 Ortho Mcneil Pharm Inc Polipéptidos tendo um único polímero solúvel em água ligado ao n-terminal por covalência
JP4541539B2 (ja) 1997-07-23 2010-09-08 ロシュ ダイアグノスティックス ゲーエムベーハー 内因性遺伝子活性化によるエリスロポエチンの製造
PT902085E (pt) 1997-09-01 2004-02-27 Aventis Pharma Gmbh Eritropoietina humana recombinante com perfil de glicosilacao vantajoso
WO1999066054A2 (en) 1998-06-15 1999-12-23 Genzyme Transgenics Corp. Erythropoietin analog-human serum albumin fusion protein
PL360581A1 (en) * 1999-05-11 2004-09-06 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration

Also Published As

Publication number Publication date
WO2003045423A1 (en) 2003-06-05
CA2468499A1 (en) 2003-06-05
US20030134795A1 (en) 2003-07-17
NZ532988A (en) 2008-04-30
EP1461065A1 (en) 2004-09-29
JP2005530678A (ja) 2005-10-13
US7232797B2 (en) 2007-06-19
AU2002357019A1 (en) 2003-06-10
BR0214557A (pt) 2006-06-06

Similar Documents

Publication Publication Date Title
TW200502385A (en) Modulation of forkhead box o1a expression
MXPA04005068A (es) Regimen de dosis de eritropoyetina para el tratamiento de la anemia.
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
SI1913947T1 (sl) Kombinirana terapija za zdravljenje raka
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
BE2012C005I2 (es)
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
SG151309A1 (en) Novel use of peptide compounds for treating pain in painful diabetic neuropathy
IL161016A0 (en) Specific binding agents of human angiopoietin-2
HK1091151A1 (en) Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
BR0313792A (pt) Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
MX2007008764A (es) Metodos para tratar capsulitis adhesiva.
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
LT2004074A (en) Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
ATE444398T1 (de) Fasergebilde mit oberflächenbehandlungszusammensetzung und eine lotionszusammensetzung
MXPA05012780A (es) Metodo para tratar estructuras fibrosas.
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
WO1999011256A8 (fr) L-threonate ferreux, composition pharmaceutique le contenant et son utilisation pour reduire et traiter l'anemie chez l'homme
SI1603584T1 (sl) Aplidin za zdravljenje multiple mieloma
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
WO2003103597A3 (en) DIAGNOSIS AND TREATMENT OF DIABETES AND INSULIN RESISTANCE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal